tradingkey.logo

Bausch + Lomb Corp

BLCO
View Detailed Chart
17.000USD
+0.590+3.60%
Close 02/06, 16:00ETQuotes delayed by 15 min
6.02BMarket Cap
LossP/E TTM

Bausch + Lomb Corp

17.000
+0.590+3.60%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.60%

5 Days

+1.80%

1 Month

-0.70%

6 Months

+20.48%

Year to Date

-0.47%

1 Year

+5.85%

View Detailed Chart

TradingKey Stock Score of Bausch + Lomb Corp

Currency: USD Updated: 2026-02-06

Key Insights

Bausch + Lomb Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 83 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 17.33.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bausch + Lomb Corp's Score

Industry at a Glance

Industry Ranking
83 / 205
Overall Ranking
222 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Bausch + Lomb Corp Highlights

StrengthsRisks
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 27.15% year-on-year.
Fairly Valued
The company’s latest PE is -19.71, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.63M shares, increasing 0.03% quarter-over-quarter.
Held by Howard Marks
Star Investor Howard Marks holds 3.25M shares of this stock.

Analyst Rating

Based on 13 analysts
Hold
Current Rating
17.333
Target Price
+5.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bausch + Lomb Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Bausch + Lomb Corp Info

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Ticker SymbolBLCO
CompanyBausch + Lomb Corp
CEOSaunders (Brenton L)
Websitehttps://ir.bausch.com/
KeyAI